Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novavax (NVAX)
:NVAX
Holding NVAX?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.66Last Year’s EPS
-1.44Same Quarter Last Year
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2018
|% Change Since: -5.33%
|Next Earnings Date:Aug 08, 2018
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments and challenges. The highlights included strategic partnerships and progress in clinical programs, while the lowlights focused on reduced financial guidance and market challenges. The overall sentiment is balanced with both promising opportunities and significant hurdles.Company Guidance
In the third quarter of 2024 earnings call for Novavax, the company provided comprehensive guidance on several key metrics and strategic initiatives. Novavax recorded total revenue of $85 million for Q3, with $38 million primarily from U.S. market sales, reflecting initial stocking orders. Despite a market share of approximately 3%, the company revised its full-year 2024 total revenue guidance to between $650 million and $700 million, down from the previous $700 million to $800 million. The full-year product sales guidance was adjusted to between $175 million and $225 million. Novavax reiterated its guidance for R&D and SG&A expenses to range between $700 million and $750 million for the year, reflecting a 40% decrease compared to 2023. Looking forward, the company aims to reduce R&D and SG&A expenses to approximately $350 million by 2026. The strategic partnership with Sanofi is expected to yield up to $700 million in near-term milestones and future tiered royalties, positioning Novavax to benefit from Sanofi's commercial capabilities in the upcoming seasons.Sanofi Partnership and Financial Milestones
Novavax has secured a partnership with Sanofi, including a $500 million upfront payment and a $70 million equity investment. The company is eligible for up to $700 million in additional milestone payments and expects to receive double-digit royalties from Sanofi sales starting in 2025.
Clinical Hold Lifted on CIC and Flu Programs
The FDA removed the clinical hold on Novavax's COVID-19 influenza combination (CIC) and stand-alone influenza vaccine candidates, allowing for Phase III trial preparations to resume.
Cost Reduction Initiatives
Novavax achieved a 26% reduction in combined R&D and SG&A expenses in Q3 2024 compared to the previous year, and plans to reduce these expenses by approximately 40% for the full year 2024.
---
NVAX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NVAX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $9.01 | $8.46 | -6.10% |
| Aug 08, 2024 | $10.71 | $11.68 | +9.06% |
| May 10, 2024 | $4.47 | $8.88 | +98.66% |
| Feb 28, 2024 | $6.02 | $4.41 | -26.74% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Novavax (NVAX) report earnings?
Novavax (NVAX) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is Novavax (NVAX) earnings time?
Novavax (NVAX) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NVAX EPS forecast?
NVAX EPS forecast for the fiscal quarter 2024 (Q4) is -0.66.
---
